Verrica Pharmaceuticals

VRCA · NASDAQ

$3.47+$0.03 (+0.87%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.44

About VRCA

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 76 full-time employees. The company went IPO on 2018-06-15. The firm's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. The company is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).

Employees: 76
Headquarters: West Chester, Pennsylvania
Listed: Jun 15, 2018
Sector: Health Care
Industry: Pharmaceuticals
Website: verrica.com

Leadership

Verrica Pharmaceuticals executives
Name	Title	Since	Age
Paul Manning	—	—	69
Jayson Rieger	—	2015	49
John Kirby	—	—	53
David Zawitz	—	—	44
Chris Chapman	—	—	—
Noah Rosenberg	—	—	58
Charles Frantzreb	—	—	36
Gavin Corcoran	—	—	62
Lawrence Eichenfield	—	—	67
Diem Nguyen	—	—	53
Mark Prygocki	—	—	59

Revenue by product and region

Fiscal year ended Dec 31, 2025: $35.58M total revenue

By product

License and collaboration revenue$20.29M57.0%
Product revenue, net$15.29M43.0%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Verrica Pharmaceuticals suppliers and customers
Company	Relationship	Country	Correlation
Torii Pharmaceutical	Supplier and customer	JP	-0.37
Lytix Biopharma LYTIX.OL	Supplier and customer	NO	—

Similar companies

Companies in the same industry as Verrica Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.